Yahoo · Aug 14, 2026
Embecta (EMBC) Q3 2026 Earnings Call Transcript
Revenue fell 8.1% year-over-year, but margin guidance rose for fiscal 2026.
EM
NYSE · EMBC
Embecta Corp.
Healthcare · Drug Manufacturers - Specialty & Generic
$5.09
Down-$0.15 (-2.86%)
Updated Sep 16, 2026, 12:45 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 699.2M
- P/E ratio
- 7.38
- Dividend yield
- 11.79%
- 52-week range
- $2.77 – $15.29
- Volume
- 703.34K
- Avg. volume
- 483.6K
Price performance
EMBC price history
1M range · 20 trading sessions · Daily adjusted prices
EMBC closed at $5.09 after 20 trading sessions, down 0.20% for the selected period.
- Last close
- $5.09
- Period change
- -0.20%
- Period low
- $4.89
- Period high
- $5.80
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.21 | $5.285 | $5.035 | $5.09 | 703.34K |
| Sep 14, 2026 | $5.00 | $5.30 | $4.98 | $5.24 | 908.75K |
| Sep 11, 2026 | $4.93 | $5.0355 | $4.89 | $4.94 | 1.13M |
| Sep 10, 2026 | $5.05 | $5.065 | $4.87 | $4.89 | 1.38M |
| Sep 9, 2026 | $5.45 | $5.60 | $5.06 | $5.12 | 1.53M |
| Sep 8, 2026 | $5.71 | $5.76 | $5.475 | $5.55 | 1.36M |
| Sep 4, 2026 | $5.63 | $5.91 | $5.60 | $5.80 | 1M |
| Sep 3, 2026 | $5.70 | $5.77 | $5.505 | $5.69 | 1.16M |
| Sep 2, 2026 | $5.27 | $5.695 | $5.27 | $5.69 | 1.3M |
| Sep 1, 2026 | $5.07 | $5.315 | $5.06 | $5.25 | 2.09M |
| Aug 31, 2026 | $5.00 | $5.235 | $4.92 | $5.14 | 2.77M |
| Aug 28, 2026 | $5.03 | $5.1793 | $4.99 | $5.05 | 1.47M |
| Aug 27, 2026 | $4.90 | $5.00 | $4.80 | $4.97 | 952.64K |
| Aug 26, 2026 | $4.98 | $5.015 | $4.89 | $4.96 | 817.06K |
| Aug 25, 2026 | $4.99 | $5.04 | $4.875 | $5.03 | 1.29M |
| Aug 24, 2026 | $5.195 | $5.275 | $4.95 | $4.99 | 991.82K |
| Aug 21, 2026 | $5.43 | $5.47 | $5.12 | $5.23 | 1.13M |
| Aug 20, 2026 | $5.32 | $5.625 | $5.32 | $5.47 | 1.62M |
| Aug 19, 2026 | $5.10 | $5.43 | $5.10 | $5.42 | 1.26M |
| Aug 18, 2026 | $5.13 | $5.38 | $5.065 | $5.10 | 1.11M |
Latest EMBC news
The latest Smart Investors Daily articles mentioning EMBC.
Stock researchCompany · Overview
EMBC research
Overview
Company profile and research snapshot.
Company profile
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $22.50
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2026 | B of A Securities | Underperform | — |
| May 6, 2026 | BTIG | Neutral | — |
| May 6, 2026 | Mizuho | Neutral | — |
| Apr 13, 2026 | Mizuho | Neutral | — |
| Feb 6, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 7, 2026
Embecta Corp. (EMBC) Q3 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q3 2026 Earnings Call August 7, 2026 8:00 AM EDTCompany ParticipantsPravesh Khandelwal - VP & Head of Investor RelationsDevdatt...
SeekingAlpha · Aug 7, 2026
Embecta Corp. 2026 Q3 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Embecta Corp.
ChartMill · Aug 7, 2026
Embecta (NASDAQ:EMBC) Jumps 9% on Strong Fiscal Q3 Earnings Beat
Embecta (EMBC) beats Q3: EPS $0.56 vs $0.27 est., revenue $271.7M vs $259.6M. Stock up 9.4% pre-market on strong earnings.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
